Prospects for an SV40 vaccine

Seminars in Cancer Biology

Volumn 11, Issue 1, 2001, Pages 81-85

  Imperiale, Michael J ^a,b,c   Pass, Harvey I ^e   Sanda, Martin G ^a,c,d  

^a Department of Microbiology and Immunology ^*  (United States)

^b Institute for Behavioral Medicine Research   (United States)

^c Center for Gene Therapy   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Gene therapy; SV40; T antigen; Vaccine; Vaccinia virus

Indexed keywords

VIRUS T ANTIGEN; VIRUS VACCINE; VIRUS VECTOR;

ARTICLE; CANCER; GENE THERAPY; IMMUNOTHERAPY; MESOTHELIOMA; MOLECULAR CLONING; NONHUMAN; SIMIAN VIRUS 40; VIRUS RECOMBINANT;

EID: 0035103470     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.2000.0349     Document Type: Article

References (39)

1. Cell and molecular biology of simian virus 40: Implications for human infections and disease
2. Surgically debulked malignant pleural mesothelioma: Results and prognostic factors
3. The importance of surgical staging in the treatment of malignant pleural mesothelioma
4. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients
5. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma
6. Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study
7. Gene therapy for lung disease: Hype or hope?
8. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: A Phase II study
9. Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma
10. A specific complement-fixing antigen present in SV40 tumor and transformed cells
11. Recognition of simian virus 40 T antigen by cytotoxic T lymphocytes
12. Cytotoxic T lymphocyte recognition sequences as markers for distinguishing among tumour antigens encoded by SV40, BKV and JCV
13. Immunization of BALB/c mice with recombinant simian virus 40 large tumor antigen induces antibody-dependent cell-mediated cytotoxicity against simian virus 40-transformed cells. An antibody-based mechanism for tumor immunity
14. Evidence of SV40 infections in hospitalized children
15. Serological evidence of SV40 infections in HIV-infected and HIV-negative adults
16. Antibodies reacting to simian virus 40 T antigen in human sera
17. SV40 neutralizing antibodies in sera of US residents without history of polio immunization
18. Occurrence of simian virus 40 (SV40)-reacting antibodies in sera of some patients with prostatic cancer
19. Prostate cancer in a transgenic mouse
20. Polyomavirus T antigens: Molecular chaperones for multiprotein complexes
21. Common and unique features of T antigens encoded by the polyomavirus group
22. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains
23. SV40-transformed simian cells support the replication of early SV40 mutants
24. Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen
25. Protection against a lethal challenge with SV40-transformed cells by the direct injection of DNA-encoding SV40 large tumor antigen
26. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases
27. Nuclear preparations of SV40-transformed cells contain tumor-specific transplantation antigen activity
28. Recognition by cytotoxic T lymphocytes of cells expressing fragments of the SV40 tumor antigen
29. Genetic control of the cytotoxic T cell response to SV40 tumor-associated specific antigen
30. SV40 large tumor antigen associated synthetic peptides define native antigenic determinants and induce protective tumor immunity in mice
31. Phase 1 trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: Comparison of intradermal versus subcutaneous administration
32. Vaccination with two different vaccinia recombinant viruses: Longterm inhibition of secondary vaccination
33. Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine
34. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer
35. Overcoming inhibition of antibody responses to a malaria recombinant vaccinia virus caused by prior exposure to wild type virus
36. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine
37. Characterization of in vivo primary and secondary CD8+ T cell responses induced by recombinant influenza and vaccinia viruses
38. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors
39. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses